Azienda Unita Sanitaria Locale Di Piacenza

At Azienda Unita Sanitaria Locale Di Piacenza, the strongest research focus is on hematologic malignancies, especially leukemia, lymphoma, and multiple myeloma. These studies aim to improve treatment effectiveness, deepen minimal residual disease assessment, and test newer targeted or chemo-free approaches for both newly diagnosed and relapsed disease.

• Studies in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myeloid leukemia seek better disease control and remission outcomes.
• Research in diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and other non-Hodgkin lymphomas is testing improved combinations and maintenance strategies.
• Trials in chronic lymphocytic leukemia and multiple myeloma are evaluating more precise, less toxic treatment options.

This department at Ospedale Guglielmo da Saliceto is clearly active in modern oncology and hematology, with a strong emphasis on personalized treatment and better long-term disease control.

The site also runs a substantial portfolio in breast cancer and selected gynecologic cancers, with studies focused on improving outcomes in early-stage, locally advanced, and metastatic disease. Many of these trials are designed to refine treatment selection, strengthen response prediction, and extend disease-free survival.

• Research in HER2-positive, HR-positive/HER2-negative, and triple-negative breast cancer is evaluating new treatment strategies and maintenance approaches.
• Trials in advanced breast cancer are exploring ways to overcome resistance after prior endocrine-based therapy.
• Studies in low-grade serous ovarian carcinoma are examining more effective options for hormonally driven disease.

The Piacenza research program reflects a strong interest in precision medicine, especially where tumor biology can guide better treatment decisions.

A major part of the clinical trial activity involves lung cancer and other thoracic tumors. The research is centered on non-small cell lung cancer, small cell lung cancer, and resectable disease, with the goal of improving survival and identifying more effective treatment combinations.

• Studies in advanced non-small cell lung cancer are testing new targeted and immunotherapy-based approaches.
• Trials in resectable NSCLC are evaluating treatment combinations before surgery to improve tumor response.
• Research in small cell lung cancer is focused on options for patients whose disease returns after prior therapy.

This work highlights the site’s interest in both immuno-oncology and personalized treatment strategies for difficult-to-treat thoracic cancers.

The clinical trial portfolio includes several studies in digestive system cancers, particularly colorectal cancer, pancreatic cancer, and oral cavity cancer. These trials aim to improve first-line treatment, post-surgical management, and long-term disease control.

• Research in metastatic colorectal cancer is comparing treatment approaches to improve progression-free survival.
• Studies in pancreatic ductal adenocarcinoma are evaluating new combinations for advanced disease.
• Trials in resected colon cancer are using circulating tumor DNA to guide more individualized postoperative care.

The breadth of gastrointestinal research at this hospital shows a clear effort to improve outcomes through earlier risk assessment and more tailored treatment planning.

Beyond cancer, the site is also active in cardiovascular disease, kidney disease, and related metabolic research. These trials are generally designed to reduce complications, protect organ function, and improve prevention strategies in high-risk patients.

• Studies in immunoglobulin A nephropathy are evaluating ways to slow kidney damage and reduce protein loss.
• Research in atherosclerotic cardiovascular disease and myocardial infarction is focused on lowering future cardiovascular risk.
• Trials in familial hypercholesterolemia and atrial fibrillation are exploring better prevention and treatment approaches.

These studies broaden the research profile of Azienda Unita Sanitaria Locale Di Piacenza beyond oncology, with attention to chronic disease prevention and long-term organ protection.

The site also contributes to studies in pain, cardiotoxicity, and other supportive-care areas that affect quality of life during treatment. These projects aim to make care safer, more tolerable, and more patient-centered across different diseases.

• Trials in acute pain in children and chronic low back pain are examining better symptom relief options.
• Research on chemotherapy-induced cardiotoxicity is looking at ways to protect the heart during cancer treatment.
• Additional studies address treatment-related complications and general clinical outcomes in complex patient populations.

This mix of research shows a broad interest in both disease-specific therapy and the everyday clinical issues that shape patient well-being.